175 related articles for article (PubMed ID: 23343765)
1. Prognostic value of LIPC in non-small cell lung carcinoma.
Galluzzi L; Goubar A; Olaussen KA; Vitale I; Senovilla L; Michels J; Robin A; Dorvault N; Besse B; Validire P; Fouret P; Behrens C; Wistuba II; Soria JC; Kroemer G
Cell Cycle; 2013 Feb; 12(4):647-54. PubMed ID: 23343765
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of vitamin B6 metabolism in lung cancer.
Galluzzi L; Vitale I; Senovilla L; Olaussen KA; Pinna G; Eisenberg T; Goubar A; Martins I; Michels J; Kratassiouk G; Carmona-Gutierrez D; Scoazec M; Vacchelli E; Schlemmer F; Kepp O; Shen S; Tailler M; Niso-Santano M; Morselli E; Criollo A; Adjemian S; Jemaà M; Chaba K; Pailleret C; Michaud M; Pietrocola F; Tajeddine N; de La Motte Rouge T; Araujo N; Morozova N; Robert T; Ripoche H; Commo F; Besse B; Validire P; Fouret P; Robin A; Dorvault N; Girard P; Gouy S; Pautier P; Jägemann N; Nickel AC; Marsili S; Paccard C; Servant N; Hupé P; Behrens C; Behnam-Motlagh P; Kohno K; Cremer I; Damotte D; Alifano M; Midttun O; Ueland PM; Lazar V; Dessen P; Zischka H; Chatelut E; Castedo M; Madeo F; Barillot E; Thomale J; Wistuba II; Sautès-Fridman C; Zitvogel L; Soria JC; Harel-Bellan A; Kroemer G
Cell Rep; 2012 Aug; 2(2):257-69. PubMed ID: 22854025
[TBL] [Abstract][Full Text] [Related]
3. Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.
Buhl IK; Santoni-Rugiu E; Ravn J; Hansen A; Christensen IJ; Jensen T; Pratt B; Askaa J; Jensen PB; Knudsen S; Sørensen JB
PLoS One; 2018; 13(3):e0194609. PubMed ID: 29566065
[TBL] [Abstract][Full Text] [Related]
4. FATS expression is associated with cisplatin sensitivity in non small cell lung cancer.
Tian Y; Zhang J; Yan S; Qiu L; Li Z
Lung Cancer; 2012 Jun; 76(3):416-22. PubMed ID: 22137560
[TBL] [Abstract][Full Text] [Related]
5. Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer.
Kenmotsu H; Ohde Y; Wakuda K; Nakashima K; Omori S; Ono A; Naito T; Murakami H; Kojima H; Takahashi S; Isaka M; Endo M; Takahashi T
Cancer Chemother Pharmacol; 2017 Sep; 80(3):609-614. PubMed ID: 28761967
[TBL] [Abstract][Full Text] [Related]
6. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.
Wang F; Lou JF; Cao Y; Shi XH; Wang P; Xu J; Xie EF; Xu T; Sun RH; Rao JY; Huang PW; Pan SY; Wang H
Exp Mol Med; 2015 May; 47(5):e162. PubMed ID: 25952770
[TBL] [Abstract][Full Text] [Related]
7. Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer.
Lin TC; Tsai LH; Chou MC; Chen CY; Lee H
Tumour Biol; 2016 Mar; 37(3):4017-23. PubMed ID: 26482622
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in Non-small cell lung cancer.
Wu F; Lu M; Qu L; Li DQ; Hu CH
Int J Clin Exp Pathol; 2015; 8(5):5457-63. PubMed ID: 26191250
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of LIPC in non-small cell lung carcinoma.
Alifano M; Damotte D
Cell Cycle; 2013 Feb; 12(4):543-4. PubMed ID: 23370388
[No Abstract] [Full Text] [Related]
10. SMYD3 overexpression indicates poor prognosis and promotes cell proliferation, migration and invasion in non‑small cell lung cancer.
Li J; Zhao L; Pan Y; Ma X; Liu L; Wang W; You W
Int J Oncol; 2020 Sep; 57(3):756-766. PubMed ID: 32705243
[TBL] [Abstract][Full Text] [Related]
11. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
Filipits M; Pirker R; Dunant A; Lantuejoul S; Schmid K; Huynh A; Haddad V; André F; Stahel R; Pignon JP; Soria JC; Popper HH; Le Chevalier T; Brambilla E
J Clin Oncol; 2007 Jul; 25(19):2735-40. PubMed ID: 17602078
[TBL] [Abstract][Full Text] [Related]
12. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
14. High ABCG4 Expression Is Associated with Poor Prognosis in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin-Based Chemotherapy.
Yang G; Wang XJ; Huang LJ; Zhou YA; Tian F; Zhao JB; Chen P; Liu BY; Wen MM; Li XF; Zhang ZP
PLoS One; 2015; 10(8):e0135576. PubMed ID: 26270652
[TBL] [Abstract][Full Text] [Related]
15. PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
Tian FM; Zhong CY; Wang XN; Meng Y
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2635-2641. PubMed ID: 28678321
[TBL] [Abstract][Full Text] [Related]
16. Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer.
Michels J; Adam J; Goubar A; Obrist F; Damotte D; Robin A; Alifano M; Vitale I; Olaussen KA; Girard P; Cremer I; Castedo M; Soria JC; Kroemer G
Ann Oncol; 2015 Dec; 26(12):2470-7. PubMed ID: 26387143
[TBL] [Abstract][Full Text] [Related]
17. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.
Zhao H; Xie YZ; Xing R; Sun M; Chi F; Zeng YC
Cell Oncol (Dordr); 2017 Aug; 40(4):357-365. PubMed ID: 28567715
[TBL] [Abstract][Full Text] [Related]
18. [Effectiveness of adjuvant chemotherapy in patient with early stages of non-small cell lung cancer depending on proliferation index of tumor].
Kolesnik AP
Lik Sprava; 2014; (1-2):110-7. PubMed ID: 24908971
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma.
Voortman J; Goto A; Mendiboure J; Sohn JJ; Schetter AJ; Saito M; Dunant A; Pham TC; Petrini I; Lee A; Khan MA; Hainaut P; Pignon JP; Brambilla E; Popper HH; Filipits M; Harris CC; Giaccone G
Cancer Res; 2010 Nov; 70(21):8288-98. PubMed ID: 20978195
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
